Rhenman & Partners Asset Management Reduces Gilead Sciences Stake

Hedge fund sells 88,000 shares of biopharmaceutical company in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB, a Swedish hedge fund, reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 52.3% in the third quarter, according to a recent SEC filing. The firm now owns 80,150 shares of the biopharmaceutical company's stock, down from 168,150 shares previously.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential future performance.

The details

According to the filing, Rhenman & Partners Asset Management sold 88,000 shares of Gilead Sciences during the third quarter. The firm's holdings in the company are now valued at $8,897,000, down from $18,697,000 at the end of the prior quarter.

  • The share sale occurred in the third quarter of 2026.

The players

Rhenman & Partners Asset Management AB

A Swedish hedge fund that has reduced its stake in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Rhenman & Partners' Gilead Sciences holdings could signal a shift in market sentiment towards the biopharmaceutical company, though more data would be needed to draw definitive conclusions. Investors will likely continue to monitor Gilead's performance and institutional ownership changes.